​Pharmacology - Repaglinide

​Pharmacology - Repaglinide 
The action of repaglinide 
Reduces the amount of glucose in the blood. Causes the release of insulin from B cells that are located in the pancreatic islets.

Method of Operation 
Sulphonylureas are analogous to this. Sulphonylurea receptor, which is a subunit of the KATP channel in the cell membrane of B cells, is responsible for the closure of the K+ channel when it interacts with the receptor. Depolarization of the cell membrane and activation of voltage-dependent Ca2+ channels are both caused by this. Interaction with Ca2+ stimulates the exocytosis of insulin.

Immediate start of activity and a brief duration of action. The half-life is one hour. Medications that stimulate hepatic P450 enzymes, such as carbamazepine, have the potential to lessen the effects of this substance. Half-life of nateglinide is 1.5 hours.

Use in Clinical Settings 
There is diabetes mellitus type 2. Postprandial hyperglycemia can be effectively controlled by the use of rapid action.
May be taken with glitazone or metformin for optimal results. Because it is primarily metabolized in the liver, it is beneficial for people who have renal insufficiency.

Adverse Effects
Unless the metabolism of the medicine is blocked by other medications, such as gemfibrozil, hypoglycemia is an uncommon occurrence.